688505Shanghai Fudan-Zhangjiang Bio-Pharmaceutical688505 info
$0.93info1.07%24h
Global rank9847
Market cap$661.33M
Change 7d-0.45%
YTD Performance-28.83%
SP500 benchmarkUnderperform
P/E0
P/S0
Revenue$0
Earnings$0
Dividend yield-
Main Sector
Healthcare
Business data

    Shanghai Fudan-Zhangjiang Bio-Pharmaceutical (688505) Stock Overview

    Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd., together with its subsidiaries, engages in the research, development, manufacture, and sale of bio-pharmaceutical products primarily in China. It offers genetic engineering platform drugs, including CD30-DM1 antibody-drug conjugate (ADC), which is in Phase I clinical trials for tumors; Trop2-SN38 ADC that is in Phase I clinical trials for triple negative, breast, bladder, gastric, and other tumors; Trop2-BB05 ADC that is in pre-clinical studies for lung cancer and triple negative breast cancer; DLL3-BB05 ADC that is in pre-clinical trials for tumors; and HER2 ADC that has carried out phase I clinical study for metastatic breast and gastric cancers. The company also provides photodynamic technical platform drugs, such as hemoporfin for port wine stain, which is in Phase IV clinical trial; and aminolevulinic acid, which is in Phase II clinical trials for cervical diseases infected by HPV and acne, as well as completed pre-clinical study for brain gliomas. In addition, it offers nano technical platform drugs, such as Doxorubicin liposome for tumors. Further, the company offers oral solid preparation technology, which includes obeticholic acid for hepatobiliary and autoimmune disease; timolol maleate cream that is in phase I clinical trials for infantile hemangioma; and FZJ-003 oral preparation, which is in Phase I clinical trials for rheumatoid arthritis, as well as in Phase II clinical trials for atopic dermatitis and ulcerative colitis. Additionally, it develops pharmaceutical and medical devices; medical diagnostic products and related services; and sells daily necessities, and clinical laboratory analysis instruments and software. It also engages in the technology development, transfer, consulting, and promotion activities; produces freeze-dried powder injections and APIs; and invests in overseas medical projects. The company was founded in 1996 and is based in Shanghai, the People's Republic of China.

    688505 Stock Information

    Symbol
    688505
    Address
    Zhangjiang Hi-Tech ParkShanghai, 201210China
    Founded
    -
    Trading hours
    9:30 AM - 3:00 PM CST
    Website
    https://www.fd-zj.com/DesktopModules/HT/chinese/home/Index.aspx
    Country
    🇨🇳 China
    Phone Number
    86 21 5895 3355

    Shanghai Fudan-Zhangjiang Bio-Pharmaceutical (688505) Price Chart

    -
    Value:-

    Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Overview: Key Details and Summary

    Stock data
    2024
    Change
    Price
    $0.9306989421949807
    N/A
    Market Cap
    $661.33M
    N/A
    Shares Outstanding
    710.57M
    N/A
    Employees
    910.00
    N/A
    logo
    Facebook Icon
    Twitter Icon
    Linkedin Icon
    © 2024 Topstocks.org